Navalign LLC’s CRISPR Therapeutics CRSP Stock Holding History

Navalign LLC’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10	Closed	-$524	–	194
2025 Q4	$524	Buy	+10	New	+$599	﹤0.01%	467

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Navalign LLC's CRSP Position: Q1 2026 in Review

Navalign LLC sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 10 shares — an estimated $524 sold.

Navalign LLC first reported a position in CRSP in Q4 2025 and held it in 1 quarter. The position peaked at $524 in Q4 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Navalign LLC reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
Navalign LLC sold 10 CRISPR Therapeutics shares in Q1 2026, an estimated $524.
Navalign LLC first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 1 quarter.
Navalign LLC's CRISPR Therapeutics position peaked at $524 in Q4 2025.
490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.